Britain ends contract with French startup for vaccines

 
 
Posted9/13/2021 7:00 AM

PARIS -- A French pharmaceutical startup announced Monday that the British government has abruptly terminated an agreement for it to supply tens of millions of COVID-19 vaccines.

Britain alleged that Valneva was in breach of its obligations under the supply agreement, which the company 'œstrenuously' denied. There was no immediate comment from the British side.

 

The vaccine, being made at Valneva's plant in Scotland, is currently in the third phase of trials and not yet approved by regulators.

Britain initially ordered 60 million doses of the vaccine and retained an option for 90 million more. It later added a further 40 million to its order. The total value of the 190 million doses is 1.4 billion euros ($1.7 billion), Valneva had said.

If the U.K. exercised all of its options, Valneva's deliveries would continue through 2025.

At the time of the deal, Britain rolled out the red carpet to the startup, while the more cautious EU dragged its feet. Valneva is clearly startled that the carpet has been pulled out from under its feet.

In its statement, Valneva, headquartered on the banks of the Loire, said it is continuing on all fronts of research and testing and is on schedule.

The VLA2001 vaccine, being made at Valneva's plant in Scotland, is currently in the third phase of trials and not yet approved by regulators.

Britain initially ordered 60 million doses of the vaccine and retained an option for 90 million more. It later added a further 40 million to its order. The total value of the 190 million doses is 1.4 billion euros ($1.7 billion), Valneva had said.

by signing up you agree to our terms of service
                                                                                                                                                                                                                       
 

If the U.K. exercised all of its options, Valneva's deliveries would continue through 2025.

At the time of the deal, Britain rolled out the red carpet to the startup, while the more cautious EU dragged its feet. Valneva is clearly startled that the carpet has been pulled out from under its feet.

In its statement, Valneva, headquartered on the banks of the Loire, said it is continuing on all fronts of research and testing and is on schedule.

0 Comments
                                                                                                                                                                                                                       
 
Article Comments
Attention: We are experiencing technical difficulties with our Facebook Comments module at this time. Comments will remain disabled until we are able to resolve the problem. We apologize for the interruption. We invite you to engage with our content and talk with other commenters on our Daily Herald Facebook page at https://www.facebook.com/DailyHeraldFans/. Thank you.